Article Text

PDF
Letter
The CTRB1-CTRB2 risk allele for chronic pancreatitis discovered in European populations does not contribute to disease risk variation in the Chinese population due to near allele fixation
  1. Xin-Ying Tang1,2,
  2. Wen-Bin Zou1,2,
  3. Emmanuelle Masson3,4,
  4. Liang-Hao Hu1,2,
  5. Claude Ferec3,4,5,6,
  6. Jian-Min Chen3,4,6,
  7. Zhao-Shen Li1,2,
  8. Zhuan Liao1,2
  1. 1 Department of Gastroenterology, Digestive Endoscopy Center, Changhai Hospital, the Second Military Medical University, Shanghai, China
  2. 2 Shanghai Institute of Pancreatic Diseases, Shanghai, China
  3. 3 Institut National de la Santé et de la Recherche Médicale (INSERM), U1078, Brest, France
  4. 4 Laboratoire de Génétique Moléculaire et d’Histocompatibilité, Centre Hospitalier Universitaire (CHU) Brest, Hôpital Morvan, Brest, France
  5. 5 Faculté de Médecine et des Sciences de la Santé, Université de Bretagne Occidentale (UBO), Brest, France
  6. 6 Etablissement Français du Sang (EFS) – Bretagne, Brest, France
  1. Correspondence to Professor Zhao-Shen Li, Department of Gastroenterology, Digestive Endoscopy Center, Changhai Hospital, the Second Military Medical University, Shanghai, 200433, China; zhaoshenli{at}hotmail.com and Dr. Zhuan Liao, Department of Gastroenterology, Changhai Hospital, the Second Military Medical University, Shanghai, China; liaozhuan{at}smmu.edu.cn

Statistics from Altmetric.com

We read with great interest the article by Rosendahl et al 1 reporting the identification of CTRB1-CTRB2 (chymotrypsin B1 and chymotrypsin B2) as a new chronic pancreatitis (CP) risk locus by means of genome-wide association study, with the lead single nucleotide polymorphism (SNP) rs8055167 having an OR of 1.35. Moreover, they found that a previously reported 16.6 kb inversion in the CTRB1-CTRB2 locus2 was in linkage disequilibrium with the CP-associated SNPs and optimally tagged by rs8048956. Furthermore, they provided in silico and in vivo evidence showing that the inversion variant changes the expression ratio of the CTRB1 and CTRB2 isoforms, the major risk allele being associated with increased CTRB1 and decreased CTRB2 mRNA expression as compared with the minor allele. Finally, they provided in vitro evidence that CTRB1 was less efficient in degrading anionic trypsinogen (PRSS2) than CTRB2 (note that rapid degradation of PRSS2 conferred by a PRSS2 missense variant protects against CP).3 Taking together, Rosendahl and colleagues concluded that …

View Full Text

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.